#Sweden #Stockholm #Sobi #Lacutamab #Innate Pharma

Sobi and Innate Pharma Launch Strategic Partnership

In a significant development within the biopharmaceutical sector, Swedish Orphan Biovitrum AB (Sobi) has announced that its strategic partnership with Innate Pharma SA has officially commenced. This announcement comes after the necessary closing conditions were satisfied, including the expiration of relevant antitrust waiting periods. The collaboration aims to expedite the advancement of lacutamab, a treatment poised to revolutionize care options for patients with cutaneous T-cell lymphoma (CTCL).

Overview of the Partnership

The partnership was initially detailed on August 10, 2026, when Sobi entered this strategic alliance to facilitate the initiation of the TELLOMAK-3 confirmatory Phase 3 study. This particular trial plays a vital role in the journey towards acquiring accelerated regulatory approval for lacutamab, specifically targeting Sézary syndrome—a rare and aggressive form of CTCL. The first patient recruitment for this trial is projected to occur in the first quarter of 2027.

Under the terms of the agreement, Innate Pharma will be responsible for conducting the TELLOMAK-3 Phase 3 trial. The outcomes of this study are expected to support regulatory submissions for accelerated approval in various jurisdictions, including Sézary syndrome and mycosis fungoides, which is the most prevalent subtype of CTCL. Sobi, upon successful regulatory approval, will hold exclusive global commercialization rights for lacutamab, with plans to assume full development rights following favorable trial results.

Financials and Milestone Opportunities

Financially, the partnership is poised to be lucrative. Upon the activation of the alliance, Sobi will remit $75 million to Innate Pharma. Furthermore, Innate could earn up to an additional $40 million based on meeting near-term developmental milestones associated with Sézary syndrome. Moreover, there is a potential for Innate to unlock up to $465 million contingent on Sobi acquiring full development rights along with achieving future regulatory and commercial success. Also, Innate will benefit from tiered royalties on net sales, reinforcing the partnership's mutual incentive structure.

The Role of Sobi

As a leading biopharmaceutical company, Sobi is committed to harnessing breakthrough innovations that significantly enhance the quality of life for individuals grappling with rare diseases. With an extensive workforce of around 2,000 employees spread across Europe, North America, the Middle East, Asia, and Australia, Sobi reported revenues of SEK 28 billion in 2025. The company’s shares are publicly traded on the Nasdaq Stockholm exchange, denoting its strong market presence and investor confidence.

Conclusion

This strategic partnership between Sobi and Innate Pharma signifies a critical step forward in the quest to provide effective therapies for CTCL, particularly Sézary syndrome. The shared expertise and financial commitment highlight the potential impact that collaboration can have on advancing medical research and providing much-needed solutions for rare diseases. With clinical trials on the horizon and an eager market awaiting new treatment options, both companies are well-positioned to make a profound difference in patient care in the coming years.